Acurx Pharmaceuticals (NASDAQ:ACXP) Receives Buy Rating from HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $8.00 price target on the stock.

Acurx Pharmaceuticals Trading Down 3.2%

Shares of ACXP opened at $0.37 on Thursday. The stock’s 50 day moving average is $0.39 and its two-hundred day moving average is $0.80. The firm has a market cap of $8.23 million, a P/E ratio of -0.34 and a beta of -1.37. Acurx Pharmaceuticals has a 12 month low of $0.30 and a 12 month high of $3.33.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. Equities research analysts forecast that Acurx Pharmaceuticals will post -0.89 EPS for the current year.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. Vanguard Capital Wealth Advisors purchased a new stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 67,500 shares of the company’s stock, valued at approximately $26,000. Vanguard Capital Wealth Advisors owned about 0.30% of Acurx Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.